BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND SPOP, TEF2, 8405, ENSG00000121067, O43791 AND Treatment
40 results:

  • 1. Endoplasmic reticulum stress-related genes as prognostic and immunogenic biomarkers in prostate cancer.
    Wan L; Fan Y; Wu T; Liu Y; Zhang R; Chen S; Zhao C; Xue Y
    Eur J Med Res; 2024 Apr; 29(1):242. PubMed ID: 38643190
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. ELK3 destabilization by speckle-type POZ protein suppresses prostate cancer progression and docetaxel resistance.
    Lee CJ; Lee H; Kim SR; Nam SB; Lee GE; Yang KE; Lee GJ; Chun SH; Kang HC; Lee JY; Lee HS; Cho SJ; Cho YY
    Cell Death Dis; 2024 Apr; 15(4):274. PubMed ID: 38632244
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Differences and Common Ground in
    Farolfi A; Armstrong WR; Djaileb L; Gafita A; Hotta M; Allen-Auerbach M; Unterrainer LM; Fendler WP; Rettig M; Eiber M; Hofman MS; Hadaschik B; Herrmann K; Czernin J; Calais J; Benz MR
    J Nucl Med; 2024 Mar; 65(3):438-445. PubMed ID: 38238041
    [No Abstract]    [Full Text] [Related]  

  • 4. Opposing Roles of
    Cavalcante L; Deshmukh SK; Ribeiro JR; Carneiro BA; Dizon DS; Angara K; Mattox T; Wu S; Xiu J; Walker P; Oberley M; Nabhan C; Huang H; Antonarakis ES
    JCO Precis Oncol; 2023 Sep; 7():e2300088. PubMed ID: 37677121
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. spop Mutations Target STING1 Signaling in prostate cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression.
    Geng C; Zhang MC; Manyam GC; Vykoukal JV; Fahrmann JF; Peng S; Wu C; Park S; Kondraganti S; Wang D; Robinson BD; Loda M; Barbieri CE; Yap TA; Corn PG; Hanash S; Broom BM; Pilié PG; Thompson TC
    Clin Cancer Res; 2023 Nov; 29(21):4464-4478. PubMed ID: 37581614
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Molecular features and race-associated outcomes of spop-mutant metastatic castration-resistant prostate cancer.
    Stangl A; Wilner C; Li P; Maahs L; Hwang C; Pilling A
    Prostate; 2023 May; 83(6):524-533. PubMed ID: 36604824
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Deregulation of spop in cancer.
    Zhang H; Jin X; Huang H
    Cancer Res; 2023 Feb; 83(4):489-499. PubMed ID: 36512624
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Intrinsic Molecular Subtypes of Metastatic Castration-Resistant prostate cancer.
    Feng E; Rydzewski NR; Zhang M; Lundberg A; Bootsma M; Helzer KT; Lang JM; Aggarwal R; Small EJ; Quigley DA; Sjöström M; Zhao SG
    Clin Cancer Res; 2022 Dec; 28(24):5396-5404. PubMed ID: 36260524
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. spop Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive prostate cancer.
    Swami U; Graf RP; Nussenzveig RH; Fisher V; Tukachinsky H; Schrock AB; Li G; Ross JS; Sayegh N; Tripathi N; Mathew Thomas V; Oxnard GR; Antonarakis ES; Agarwal N
    Clin Cancer Res; 2022 Nov; 28(22):4917-4925. PubMed ID: 36088616
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Genomic Features of Lung-Recurrent Hormone-Sensitive prostate cancer.
    Fonseca NM; Van der Eecken K; Herberts C; Verbeke S; Ng SWS; Lumen N; Ritch E; Murtha AJ; Bernales CQ; Schönlau E; Moris L; Van Dorpe J; Annala M; Wyatt AW; Ost P
    JCO Precis Oncol; 2022 Apr; 6():e2100543. PubMed ID: 35507889
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. FLG Gene Mutation Up-regulates the Abnormal Tumor Immune Response and Promotes the Progression of prostate cancer.
    Zhang P; An Z; Sun C; Xu Y; Zhang Z
    Curr Pharm Biotechnol; 2022; 23(14):1658-1670. PubMed ID: 35422210
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. OTUD6A promotes prostate tumorigenesis via deubiquitinating Brg1 and AR.
    Fu X; Zhao J; Yu G; Zhang X; Sun J; Li L; Yin J; Niu Y; Ren S; Zhu Y; Xu B; Huang L
    Commun Biol; 2022 Mar; 5(1):182. PubMed ID: 35233061
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. BoxCar and shotgun proteomic analyses reveal molecular networks regulated by UBR5 in prostate cancer.
    Yan Y; Zhou B; Lee YJ; You S; Freeman MR; Yang W
    Proteomics; 2022 Feb; 22(4):e2100172. PubMed ID: 34897998
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Clinical and genomic features of spop-mutant prostate cancer.
    Nakazawa M; Fang M; H Marshall C; Lotan TL; Isaacsson Velho P; Antonarakis ES
    Prostate; 2022 Feb; 82(2):260-268. PubMed ID: 34783071
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. spop mutation induces DNA methylation via stabilizing GLP/G9a.
    Zhang J; Gao K; Xie H; Wang D; Zhang P; Wei T; Yan Y; Pan Y; Ye W; Chen H; Shi Q; Li Y; Zhao SM; Hou X; Weroha SJ; Wang Y; Zhang J; Karnes RJ; He HH; Wang L; Wang C; Huang H
    Nat Commun; 2021 Sep; 12(1):5716. PubMed ID: 34588438
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer.
    Tewari AK; Cheung ATM; Crowdis J; Conway JR; Camp SY; Wankowicz SA; Livitz DG; Park J; Lis RT; Bosma-Moody A; He MX; AlDubayan SH; Zhang Z; McKay RR; Leshchiner I; Brown M; Balk SP; Getz G; Taplin ME; Van Allen EM
    Cell Rep; 2021 Sep; 36(10):109665. PubMed ID: 34496240
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Long non-coding RNAs correlate with genomic stability in prostate cancer: A clinical outcome and survival analysis.
    Jianfeng W; Yutao W; Jianbin B
    Genomics; 2021 Sep; 113(5):3141-3151. PubMed ID: 34174340
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Loss of Speckle-Type POZ Protein Promotes prostate cancer Cell Migration and Invasion Through Upregulation of MCP-1.
    Shi J; Cao J; Lu X; Fan L; Guo H; Fu J
    Med Sci Monit; 2021 Apr; 27():e929199. PubMed ID: 33872295
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Mutated spop E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and prostate cancer Progression.
    Shi L; Yan Y; He Y; Yan B; Pan Y; Orme JJ; Zhang J; Xu W; Pang J; Huang H
    Cancer Res; 2021 Jul; 81(13):3593-3606. PubMed ID: 33762355
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Patient-derived xenografts and organoids model therapy response in prostate cancer.
    Karkampouna S; La Manna F; Benjak A; Kiener M; De Menna M; Zoni E; Grosjean J; Klima I; Garofoli A; Bolis M; Vallerga A; Theurillat JP; De Filippo MR; Genitsch V; Keller D; Booij TH; Stirnimann CU; Eng K; Sboner A; Ng CKY; Piscuoglio S; Gray PC; Spahn M; Rubin MA; Thalmann GN; Kruithof-de Julio M
    Nat Commun; 2021 Feb; 12(1):1117. PubMed ID: 33602919
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.